Ajanta Pharma · NSE: AJANTPHARM · BSE: 532331
Q2 FY25 results · Jul–Sep 2024
Ajanta Pharma reported revenue from operations of ₹1,186.64 crore (up 15.4% from Q2 FY24) and net profit of ₹216.48 crore (up 10.8% from Q2 FY24) for Q2 FY25 (Jul–Sep 2024), on a consolidated basis.
| Item | Q2 FY25 | Q2 FY24 | YoY | Q1 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,186.64 | 1,028.44 | +15.4% | 1,144.92 | +3.6% |
| Other income | 19.48 | 21.33 | −8.7% | 26.47 | −26.4% |
| Total income | 1,206.12 | 1,049.77 | +14.9% | 1,171.39 | +3.0% |
| Profit before tax | 290.24 | 275.94 | +5.2% | 322.12 | −9.9% |
| Net profit for the period | 216.48 | 195.30 | +10.8% | 245.77 | −11.9% |
| EPS, basic (₹) | 17.27 | 15.51 | +11.3% | 19.54 | −11.6% |
| Net margin (%) | 18.2 | 19.0 | 21.5 |
| Item | Q2 FY25 | Q2 FY24 | YoY | Q1 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,128.91 | 945.18 | +19.4% | 1,077.27 | +4.8% |
| Other income | 40.34 | 52.16 | −22.7% | 28.37 | +42.2% |
| Total income | 1,169.25 | 997.34 | +17.2% | 1,105.64 | +5.8% |
| Profit before tax | 309.20 | 290.50 | +6.4% | 310.56 | −0.4% |
| Net profit for the period | 234.98 | 212.36 | +10.7% | 236.03 | −0.4% |
| EPS, basic (₹) | 18.75 | 16.87 | +11.1% | 18.77 | −0.1% |
| Net margin (%) | 20.8 | 22.5 | 21.9 |
Consolidated
- Filed with BSE
- 29 Oct 2024, 11:16 IST
- Board meeting
- 28 Oct 2024
- Period
- 01 Jul 2024 to 30 Sep 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 29 Oct 2024, 11:16 IST
- Board meeting
- 28 Oct 2024
- Period
- 01 Jul 2024 to 30 Sep 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE